Abstract 4929: CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel

Abstract CAR-T cell therapies have shown remarkable success in hematologic malignancies; however, their efficacy in solid tumors remains limited. This is primarily due to the complex tumor microenvironment (TME), which creates immunosuppressive conditions and physical barriers that hinder CAR-T infiltration and function. Current in vitro models fail to replicate these critical parameters, limiting the ability to predict clinical performance. To address this gap, we developed a tumor-vasculature-on-chip model using the OrganoPlate platform, enabling perfusion of CAR-T cells through a functional endothelial vessel adjacent to a tumor compartment. This setup allows assessment of key processes such as extravasation, migration, and killing kinetics in a physiologically relevant context. EpCAM-positive HT-29 colorectal cancer cells and EpCAM-negative A375 melanoma cells were co-cultured with an endothelial tubule to evaluate EpCAM-targeting CAR-T cells. CAR-T cells selectively killed EpCAM-positive HT-29 cells while sparing EpCAM-negative A375 cells, demonstrating antigen-specific activity. Killing was dose-dependent, and endothelial integrity was maintained at most CAR-T concentrations but disrupted at the highest doses, revealing a therapeutic window. We further compared CAR-T constructs with different co-stimulatory domains (CD28 vs. 4-1BB) and observed reduced potency with 4-1BB. Addition of IL-2 enhanced CAR-T cytotoxicity. Cytokine profiling showed increased IFN-γ, TNF-α, and IL-6 over time, and morphometric analysis confirmed endothelial disruption at high effector-to-target ratios. The platform was also used to study combination strategies, including immune checkpoint inhibitors and temozolomide. This modular, scalable organ-on-chip system enables phenotypic and functional characterization of CAR-T cells under relevant conditions. Citation Format: Luuk de Haan, Aleksandra Olczyk, Thomas Olivier, Joris Wesselius, Will Allen, Johnny Suiker, Todd Burton, Lenie van den Broek, Karla Queiroz, . CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4929.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-4929
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4929: CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel

Joris Wesselius, Lenie van den Broek, Luuk de Haan, Aleksandra Olczyk et al.
Cancer Research
CAR-T cell therapy research
article

Abstract 4929: CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel

Joris Wesselius, Lenie van den Broek, Luuk de Haan, Aleksandra Olczyk, Karla Queiroz, T. Burton, Johnny Suiker, Thomas Olivier, Will Allen
article en

Abstract

Abstract CAR-T cell therapies have shown remarkable success in hematologic malignancies; however, their efficacy in solid tumors remains limited. This is primarily due to the complex tumor microenvironment (TME), which creates immunosuppressive conditions and physical barriers that hinder CAR-T infiltration and function. Current in vitro models fail to replicate these critical parameters, limiting the ability to predict clinical performance. To address this gap, we developed a tumor-vasculature-on-chip model using the OrganoPlate platform, enabling perfusion of CAR-T cells through a functional endothelial vessel adjacent to a tumor compartment. This setup allows assessment of key processes such as extravasation, migration, and killing kinetics in a physiologically relevant context. EpCAM-positive HT-29 colorectal cancer cells and EpCAM-negative A375 melanoma cells were co-cultured with an endothelial tubule to evaluate EpCAM-targeting CAR-T cells. CAR-T cells selectively killed EpCAM-positive HT-29 cells while sparing EpCAM-negative A375 cells, demonstrating antigen-specific activity. Killing was dose-dependent, and endothelial integrity was maintained at most CAR-T concentrations but disrupted at the highest doses, revealing a therapeutic window. We further compared CAR-T constructs with different co-stimulatory domains (CD28 vs. 4-1BB) and observed reduced potency with 4-1BB. Addition of IL-2 enhanced CAR-T cytotoxicity. Cytokine profiling showed increased IFN-γ, TNF-α, and IL-6 over time, and morphometric analysis confirmed endothelial disruption at high effector-to-target ratios. The platform was also used to study combination strategies, including immune checkpoint inhibitors and temozolomide. This modular, scalable organ-on-chip system enables phenotypic and functional characterization of CAR-T cells under relevant conditions. Citation Format: Luuk de Haan, Aleksandra Olczyk, Thomas Olivier, Joris Wesselius, Will Allen, Johnny Suiker, Todd Burton, Lenie van den Broek, Karla Queiroz, . CAR-Tmigration andcytotoxicity in atumor-vasculature-on-chipmodel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4929.

Cancer ResearchVol. 86(7_Supplement)
Mimetas (Netherlands) (NL)
Openalex Percentile: Top 32%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.